BIOVIE INC. (BIVI) Form 10-Q — May 11, 2026
BioVie Inc. reported a net loss of approximately $16.4 million for the nine months ended March 31, 2026, compared to a net loss of $14.1 million for the same period in 2025. The increase in net loss was primarily due to higher research and development expenses, particularly in the Sunrise PD Phase 2 study and the Long COVID Phase 2 study. The company has a significant accumulated deficit of approximately $368.6 million as of March 31, 2026, and has not generated any revenue.
Key figures
- Eps
- 0
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -16,427,331
- Total Debt
- 1,907,029
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 17,514,621
- Cash Position
- 13,098,976
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 7,541,839
- Reverse split ratio
- 1:10
Price after filing
Close on the filing date to close N calendar days later (from $1.35). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.